Market capitalization | $377.22m |
Enterprise Value | $364.39m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.26 |
P/S ratio (TTM) P/S ratio | 6.48 |
P/B ratio (TTM) P/B ratio | 15.32 |
Revenue growth (TTM) Revenue growth | -34.73% |
Revenue (TTM) Revenue | $58.20m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
2 Analysts have issued a G1 Therapeutics, Inc. forecast:
2 Analysts have issued a G1 Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 58 58 |
35%
35%
|
|
Gross Profit | 52 52 |
38%
38%
|
|
EBITDA | -37 -37 |
43%
43%
|
EBIT (Operating Income) EBIT | -38 -38 |
43%
43%
|
Net Profit | -45 -45 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Head office | United States |
CEO | Josh Franklin |
Employees | 100 |
Founded | 2008 |
Website | www.g1therapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.